Normobaric Hyperoxia Slows Blood–Brain Barrier Damage and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in Cerebral Ischemia

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.

BACKGROUND AND PURPOSE Prolonged ischemia causes blood-brain barrier (BBB) damage and increases the incidence of neurovasculature complications secondary to reperfusion. Therefore, targeting ischemic BBB damage pathogenesis is critical to reducing neurovasculature complications and expanding the therapeutic time window of tissue-type plasminogen activator (tPA) thrombolysis. This study investig...

متن کامل

A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia

Cerebrovascular homeostasis is maintained by the blood-brain barrier (BBB), which forms a mechanical and functional barrier between systemic circulation and the central nervous system (CNS). In patients with ischemic stroke, the recombinant tissue-type plasminogen activator (rt-PA) is used to accelerate recanalization of the occluded vessels. However, rt-PA is associated with a risk of increasi...

متن کامل

The New Time Window for Tissue Plasminogen Activator in Stroke

The publication of the National Institute of Neurological Diseases and Stroke trial 13 years ago was one of the most exciting events in modern stroke medicine, demonstrating the powerful effect of tissue plasminogen activator (tPA) in acute ischemic stroke within 3 hours of symptom onset.1 The sound barrier for stroke treatment had been broken. The European Cooperative Acute Stroke Study III (E...

متن کامل

Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.

BACKGROUND AND PURPOSE A major limitation of tissue plasminogen activator (tPA) thrombolysis for ischemic stroke is the narrow time window for safe and effective therapy. Delayed tPA thrombolysis increases the risk of cerebral hemorrhage and mortality, which, in part, is related to neurovascular proteolysis mediated by matrix metalloproteinases (MMPs). We recently showed that normobaric hyperox...

متن کامل

Tissue Plasminogen Activator and Time to Treatment

Tissue Plasminogen Activator and Time to Treatment The National Institute of Neurological Disorders and Stroke studies, published in 1995, demonstrated for the first time that in patients selected by clinical and noncontrast computed tomography criteria, intravenous TPA (IV tissue plasminogen activator) resulted in improved outcomes compared with standard treatment. Since that time, safe and qu...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Stroke

سال: 2015

ISSN: 0039-2499,1524-4628

DOI: 10.1161/strokeaha.114.008599